XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisition of Business
 6 Months Ended 12 Months Ended
Jul. 31, 2021
Jan. 31, 2021
Business Combinations [Abstract]    
ACQUISITION OF BUSINESS
  3. ACQUISITION OF BUSINESS

 

On August 31, 2020, the Company entered into a Purchase Agreement (“Agreement”), with Pocono Coated Products (“PCP”), pursuant to which PCP agreed to sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business, including: (1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free and clear of all liens, except for certain lease obligations, and (2), a 100% membership interest in Active Intelligence, LLC (collectively the “Assets”). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary of the Company. The purchase price for the Assets was (i) $6,085,180 paid with the issuance of 608,519 shares in the Company’s common stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the “Shares”), and (ii) a promissory note of the Company, net of debt discount, in the principal amount, of $1,332,893 (the Note”) which is due upon the earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $4,000,000 and/or a public offering of no less than $4,000,000. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period of one year at the annual meeting of shareholders of the Company held in October 2020.

 

The Agreement provides that it is effective August 31, 2020, on which date the parties also entered into an escrow agreement (the “Escrow Agreement”), with legal counsel serving as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special purpose subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also entered into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.

 

The purpose of the Company entering into the transaction is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated to the net tangible assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and, as such, the transaction was accounted for under the acquisition method of accounting.

 

Details of the net assets acquired are as follows:

 

   Fair value 
   Recognized on 
   Acquisition 
Common stock issued  $6,085,180 
Note payable issued   1,332,893 
   $7,418,073 
      
Cash  $66,994 
Accounts receivable   1,761 
Inventory   42,613 
Equipment and fixtures   1,056,935 
Customer base   177,600 
Intellectual property and trademarks   583,200 
Goodwill   5,810,640 
Accounts payable and accrued expenses   (26,104)
Deferred revenue   (26,851)
Debt   (268,715)
Net assets acquired  $7,418,073 

  

The following unaudited pro forma condensed financial information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and Active Intelligence, as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated results of operations of the Company.

 

   Six Months Ended 
   July 31, 
   2020 
   As Reported   Proforma 
Net revenue  $203,814   $629,873 
Net loss   (638,063)   (702,975)
Loss per common share - basic and diluted   (0.12)   (0.12)
2. ACQUISITION OF BUSINESS

 

On August 31, 2020, the Company entered into a Purchase Agreement (“Agreement”), with Pocono Coated Products (“PCP”), pursuant to which PCP agreed to sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business, including: (1) all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free and clear of all liens, except for certain lease obligations, and (2), a 100% membership interest in Active Intelligence, LLC (collectively the “Assets”). The net assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary of the Company. The purchase price for the Assets was (i) $6,085,180 paid with the issuance of 608,519 shares in the Company’s common stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the “Shares”), and (ii) a promissory note of the Company, net of debt discount, in the principal amount, of $1,332,893 (the Note”) which is due upon the earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of not less than $4,000,000 and/or a public offering of no less than $4,000,000. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period of one year at the annual meeting of shareholders of the Company held in October 2020.

 

The Agreement provides that it is effective August 31, 2020, on which date the parties also entered into an escrow agreement (the “Escrow Agreement”), with legal counsel serving as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special purpose subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also entered into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement.

 

The purpose of the Company entering into the transaction is to enhance the transdermal products operations of the Company. The fair value of consideration given was allocated to the net tangible assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and, as such, the transaction was accounted for under the acquisition method of accounting.

 

Details of the net assets acquired are as follows:

 

   Fair value
Recognized
on
Acquisition		 
Common stock issued  $6,085,180 
Note payable issued   1,332,893 
   $7,418,073 
Cash  $66,994 
Accounts receivable   1,761 
Inventory   42,613 
Equipment and fixtures   1,056,935 
Customer base   177,600 
Intellectual property and trademarks   583,200 
Goodwill   5,810,640 
Acounts payable and accrued expenses   (26,104)
Deferred revenue   (26,851)
Debt   (268,715)
Net assets acquired  $7,418,073 

 

The following unaudited pro forma condensed financial information presents the combined results of operations of the Company and the two businesses acquired from PCP, Pocono and Active Intelligence, as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated results of operations of the Company.

 

   January 31, 
   2021   2020 
   As       As     
   Reported   Proforma   Reported   Proforma 
Net revenue  $943,702   $1,369,761   $370,647   $1,993,472 
                     
Net loss   (2,932,828)   (3,001,178)   (2,766,627)   (2,732,727)
                     
Loss per common share - basic and diluted   (0.51)   0.52    (0.50)   (0.45)

 

Since the date of acquisition, Pocono and Active Intelligence had net revenues of $154,195 and incurred a net loss of $40,068.